GHRP-6GH Secretagogue PeptideSafety Rating 6/10

TypeSynthetic hexapeptide GH secretagogue
CAS87616-84-0
MW873.01 g/mol
AAs6
Primary research areaGrowth hormone secretagogue research

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeLimited clinical data; research doses 100 mcg 2–3x daily (~1 mcg/kg)source ↗
AdministrationSubcutaneous injection
Half-life~15–60 minutes
Safety6/10 · Not FDA-approved
NCAA D1Banned

Price Comparison

Compare vendors · per 10mg

11 vendors competing

VendorPrice$ / mgUpdated
Core PeptidesBest $/mgCOA ✓ · 3P$29.00$2.90Apr 16, 2026Buy →
SomaChemsCOA ✓ · 3P$15.99$19.99−20% · code PEPTIDEPRICES$3.20May 14, 2026Buy →
Swiss ChemsCOA ✓ · 3P$179.95$3.60Apr 17, 2026Buy →
$25 off $100+·auto
Swiss ChemsCOA ✓ · 3P$19.95$3.99Apr 17, 2026Buy →
$25 off $100+·auto
Core PeptidesCOA ✓ · 3P$20.00$4.00Apr 16, 2026Buy →

Overview

About GHRP-6

Mechanism of action

Hexapeptide ghrelin mimetic; binds GHS-R1a; stimulates GH and IGF-1; increases appetite significantly via hypothalamic ghrelin pathways; gastric motility enhancement.

Safety profile

Strong appetite increase (advantage or disadvantage), water retention, cortisol/prolactin elevation, fatigue, hypoglycemia risk if not eating. · Human studies exist; stronger hunger/cortisol response than GHRP-2; water retention; tolerable

Storage

Stability & handling

❄️Lyophilized (powder)−20°Clong-term stable
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on GHRP-6

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), first characterized by Bowers et al. (Endocrinology 1984), acts as a synthetic agonist of the ghrelin/GHS-R1a receptor to potently stimulate pituitary GH release via both hypothalamic GHRH amplification and direct pituitary PI turnover — with maximal GH release requiring intact endogenous GHRH (Pandya et al., JCEM 1998).
  • Beyond GH secretagogue activity, GHRP-6 exhibits potent cytoprotective and cardioprotective properties via CD36 and GHS-R1a receptor signaling: in an acute myocardial infarction model, GHRP-6 reduced infarct mass by 78% and decreased myocardial necrosis — effects now categorized as a distinct pharmacological class independent of GH secretion.

8 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch